围手术期替罗非班应用对行DES置入老年冠心病患者出血、血小板减少及MACE发生风险的影响

发布时间：2018-06-04 05:25

本文选题：替罗非班 + 抗血小板　；参考：《中国医院药学杂志》2017年04期

【摘要】：目的:探讨替罗非班围手术期应用对行药物洗脱支架(DES)置入老年冠心病患者出血、血小板减少及主要不良心血管事件(MACE)发生风险的影响。方法:研究对象选取某院2011年1月-2015年6月收治行DES置入老年冠心病患者共200例,采用随机数字表法分为对照组(100例)和观察组(100例),分别在术后给予常规二联抗血小板方案单用和在此基础上加用替罗非班治疗,比较2组患者TIMI出血分级情况、血小板减少率及随访MACE发生率等。结果:2组患者TIMI出血分级情况比较差异无统计学意义(P0.05);2组患者血小板减少率比较差异无统计学意义(P0.05);同时观察组患者随访MACE发生率显著低于对照组,差异有统计学意义(P0.05)。结论:替罗非班围手术期应用用于行DES置入老年冠心病患者可有效降低远期MACE发生风险,改善临床预后,且未导致术后出血和血小板减少情况加重。
[Abstract]:Objective: to investigate the effect of perioperative use of tirofiban on the risk of bleeding, thrombocytopenia and major adverse cardiovascular events in elderly patients with coronary heart disease (CHD) by drug-eluting stents (des). Methods: a total of 200 elderly patients with coronary heart disease were treated with DES from January 2011 to June 2015. The patients in the observation group were divided into control group (n = 100) and observation group (n = 100). The patients in the two groups were treated with routine anti-platelet regimen and tirofiban respectively. The bleeding grade of TIMI was compared between the two groups. The rate of thrombocytopenia and the incidence of MACE were followed up. Results there was no significant difference in TIMI bleeding grade between the two groups. There was no significant difference in the thrombocytopenia rate between the two groups. The incidence of MACE in the observation group was significantly lower than that in the control group (P 0.05). Conclusion: the perioperative application of tirofiban for DES implantation in elderly patients with coronary heart disease can effectively reduce the risk of long-term MACE and improve the clinical prognosis without exacerbating postoperative bleeding and thrombocytopenia.
【作者单位】：沧州市中心医院心内二科;
【分类号】：R541.4

【相似文献】